Education and experience
– Liv Hospital Ulus Medical Executive Board Member (2021-...)
– Istinye University, Faculty of Medicine, Full Professor (2017-…)
– Istinye University, Faculty of Medicine, Associate Professor (2016-2017)
– Liv Hospital Radiation Medicine Center, Tibilisi, Georgia, Radiation Oncologist, Consultant (2016-2019)
– Liv Hospital, Ulus, Istanbul, Turkey, Head of Dept. of Radiation Oncology Radyasyon Onkolojisi (2015-…)
– Istanbul University Institute of Oncology, Associate Professor (2012-2015)
– Visiting scholar; Stereotactic Radiotherapy, Thoracic Oncology, University of North Carolina, NC, USA (2010-2011)
– Kocaeli University, Faculty of Medicine, Dept. of Radiation Oncology, Asistant Professor (2006-2009)
– Gulhane Military Medical Academy, Dept. of Radiation Oncology, Radiation oncologist (Military service) (2004-2005)
– Istanbul University, Istanbul Faculty of Medicine, Dept. of Radiation Oncology, Residency (1999-2004)
– Istanbul University, Istanbul Faculty of Medicine, Licence (1993-1999)
– Istinye University, Faculty of Medicine, Full Professor (2017-…)
– Istinye University, Faculty of Medicine, Associate Professor (2016-2017)
– Liv Hospital Radiation Medicine Center, Tibilisi, Georgia, Radiation Oncologist, Consultant (2016-2019)
– Liv Hospital, Ulus, Istanbul, Turkey, Head of Dept. of Radiation Oncology Radyasyon Onkolojisi (2015-…)
– Istanbul University Institute of Oncology, Associate Professor (2012-2015)
– Visiting scholar; Stereotactic Radiotherapy, Thoracic Oncology, University of North Carolina, NC, USA (2010-2011)
– Kocaeli University, Faculty of Medicine, Dept. of Radiation Oncology, Asistant Professor (2006-2009)
– Gulhane Military Medical Academy, Dept. of Radiation Oncology, Radiation oncologist (Military service) (2004-2005)
– Istanbul University, Istanbul Faculty of Medicine, Dept. of Radiation Oncology, Residency (1999-2004)
– Istanbul University, Istanbul Faculty of Medicine, Licence (1993-1999)
Specialties
– Breast, Gynecologic cancers
– Head and Neck cancers
– Urologic cancers, gastrointestinal cancers
– Lung cancer
– Central nervous tumors and metastases
– Skin cancers
– Soft tissue tumors
– Four-Dimensional (4D) Radiotherapy
– Stereotactic RT
– IMRT
– 4D real time TRUS based HDR prastate brachytherapy
– 3D Brachytherapy (gynecologic + interstitial + hybrid aplicators)
– Head and Neck cancers
– Urologic cancers, gastrointestinal cancers
– Lung cancer
– Central nervous tumors and metastases
– Skin cancers
– Soft tissue tumors
– Four-Dimensional (4D) Radiotherapy
– Stereotactic RT
– IMRT
– 4D real time TRUS based HDR prastate brachytherapy
– 3D Brachytherapy (gynecologic + interstitial + hybrid aplicators)
Device experiences
1- Unity 1.5 Tesla MR-Linac (onsite and online adaptive radiotherapy with 1.5 tesla guidance)
2- Versa HD (4-D IG-IMRT, Linac-based stereotactic radiotherapy/radosurgery, sentinel, catalyst)
3- Flexitron (4 dimensional real-time TRUS guided prostate HDR brachytherapy, 3 dimensional brachytherapy, 20 channels)
4- True Beam-STx (3-D IG-IMRT, Linac-based stereotactic radiotherapy/radosurgery)Intrabeam (introperative kv radiotherapy)
5- Cyberknife (Robotik stereotactic radiotherapy)
6- Intrabeam (Intraoperative radiotherapy)
7- Trilogy-Rapid arc (3-D IG-IMRT)
8- Tomotherapy (3-D IG-IMRT)
9- DBX (IG-IMRT, 3-D conformal RT)
10- Nucletron mikroselektron (3-D Brachytherapy)
11- Gammamed plus (3-D Brachytherapy)
12- Oncor Impression (3-D conformal RT))
13- Primus (33-D conformal RT))
14- Cirus, Terabalt (Co-60 teletherapy device)
15- Stabilipan (kilovoltage X-ray, skin/subcutaneous RT)
16- Philips Brilliant big-bore 4D computed tomography
17- Nucletron oldeft (comventional simulator)
2- Versa HD (4-D IG-IMRT, Linac-based stereotactic radiotherapy/radosurgery, sentinel, catalyst)
3- Flexitron (4 dimensional real-time TRUS guided prostate HDR brachytherapy, 3 dimensional brachytherapy, 20 channels)
4- True Beam-STx (3-D IG-IMRT, Linac-based stereotactic radiotherapy/radosurgery)Intrabeam (introperative kv radiotherapy)
5- Cyberknife (Robotik stereotactic radiotherapy)
6- Intrabeam (Intraoperative radiotherapy)
7- Trilogy-Rapid arc (3-D IG-IMRT)
8- Tomotherapy (3-D IG-IMRT)
9- DBX (IG-IMRT, 3-D conformal RT)
10- Nucletron mikroselektron (3-D Brachytherapy)
11- Gammamed plus (3-D Brachytherapy)
12- Oncor Impression (3-D conformal RT))
13- Primus (33-D conformal RT))
14- Cirus, Terabalt (Co-60 teletherapy device)
15- Stabilipan (kilovoltage X-ray, skin/subcutaneous RT)
16- Philips Brilliant big-bore 4D computed tomography
17- Nucletron oldeft (comventional simulator)
Memberships
– TROD (Türk Radyasyon Onkolojisi Derneği)
– ASCO (American Soicety of Clinical Oncology)
– ASTRO (American Society for Radiation Oncology)
– ESTRO (European Society for Radiation Oncology)
– Society of Neurooncology
– ASCO (American Soicety of Clinical Oncology)
– ASTRO (American Society for Radiation Oncology)
– ESTRO (European Society for Radiation Oncology)
– Society of Neurooncology
Research and publications
1. Fayda M. Having ypN0 may not be enough to abandon the Postmastectomy Radiotherapy (PMRT) in Her-2 positive patients. Radiother Oncol. 2023 Aug;185:109722. doi: 10.1016/j.radonc.2023.109722. Epub 2023 May 25. PMID: 37244359.
2. Ozen A, Fayda M. Cardiotoxicity After the Lymphoma. Turk J Oncol 2022;37(Supp 1):44–50
3. Türkkan G, Fayda M. Abdominopelvik oligometastatik hastalıkta MRgRT. Özyar E, Önal HC, Fayda M, Selek U, editörler. Radyoterapide Yeni Bir Teknoloji: MR-Linak'ın Güncel Kullanımı. 1. Baskı. Ankara: Türkiye Klinikleri; 2022. p.57-61
4. Turkkan G, Bilici N, Sertel H, Keskus Y, Alkaya S, Tavli B, Ozkirim M, Fayda M. Clinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy. Front Oncol. 2022 Aug 16;12:909402. doi: 10.3389/fonc.2022.909402. PMID: 36052268; PMCID: PMC9424496.
5. Tambas M, Tavli B, Bilici N, Dizman A, Sertel H, Fayda M. Computed Tomography-Guided Optimization of Needle Insertion for Combined Intracavitary/Interstitial Brachytherapy With Utrecht Applicator in Locally Advanced Cervical Cancer. Pract Radiat Oncol. 2021 Jul-Aug;11(4):272-281. doi: 10.1016/j.prro.2021.01.008. Epub 2021 Feb 5. PMID: 33556579.
6. Turkkan, G, Bilici N, Sertel H, Tavlı B, Özkırım M, Fayda M. Dosimetric Comparison of Volumetric Modulated Arc Therapy and Dynamic Conformal Arc Therapy in Three fraction Single-isocenter Stereotactic Radiosurgery for Multiple Brain Metastases. Turk J Oncol 2022;37(1):67–73
7.Onder S, Fayda M, Karanlık H, Bayram A, Şen F, Cabioglu N, Tuzlalı S, İlhan R, ve Yavuz E. Loss of ARID1A expression is associated with poor prognosis in invasive micropapillary carcinomas of the breast: A clinicopathologic and immunohistochemical study with long-term survival analysis. Breast J. 2017 May 23. doi: 10.1111/tbj.12823. [Epub ahead of print]
8. Tambaş M, Fayda M. Yaşlıda Santral Sinir Sistemi Kanserleri. Saka B, editör. Geriatrik Onkoloji. Ankara: Türkiye Klinikleri; 2018. p. 28-35.
9. Fayda M, Gezer U. GAS5 oligonucleotides as therapeutic agents in breast cancer. Transl Cancer Res doi: 10.21037/tcr.2016.08.4 (2016).
10. Fayda M, Isin M, Tambas M, Guveli M, Meral R, Altun M, Sahin D, Ozkan G, Sanli Y, Isin H, Ozgur E, Gezer U. Do Circulating Long Non-Coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) Predict the Treatment Response in Patients with Head and Neck Cancer Treated with Chemoradiotherapy? Tumor Biology, 2015, 19 October, DOI: 10.1007/s13277-015-4189-1.
11. Fayda M, Tambaş, M, Karanlık H. Is sentinel lymph node biopsy enough for axillary macrometastasis? Turkish Journal of Surgery, 2015, Vol 31(4), pp. 253-255.
12. Aydiner A, Sen F, Tambas M, Ciftci R, Eralp Y, Saip P, Karanlik H, Fayda M, Kucucuk S, Onder S, Yavuz E, Muslumanoglu M, Igci A.Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment. Medicine (Baltimore), 2015 Dec;94(52):e2341.
13. Karanlık H, Özgür İ, Şahin D, Fayda M, Önder S, Yavuz E. Intraoperative ultrasound reduces the need for re-excision in breast conserving surgery, World Journal of Surgical Oncology, 2015 Nov 24;13(1):321.
14. Goldin G., Zagar T., Carter J., Fayda M, Prasad S., Fakiris S., Chen R., Morris D., Marks L., Schreiber E., Stereotactic Body Radiation Therapy For Early Stage Lung Cancer:Quantifying The Effect Of Tracking With Respiratory Motion On Chest Wall Dosimetry, American Society for Radiation Oncology 55th Annual Meeting, USA, 22-25 September 2013, vol.87, pp.733-734
15. Çakır A, Akgün Z, Fayda M, Ağaoğlu F. Comparison of three dimensional conformal radiation therapy, intensity modulated radiation therapy and volumetric modulated arc therapy for low radiation exposure of normal tissue in patients with prostate cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16(8), 3365-3370.
16. Fried D., Miller S., Fayda M, Morris D., Zagar T., Lawrence M., Schreiber E., Ivanoviç M., Mccartney W., Marks L., “Estimating The Alpha/Beta Ratio For Radiation-Induced Ct Density Changes In Patients Receiving Thoracic Radiation: Comparison Of Data From Srs And Conventional Fractionation”, 54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), BOSTON, ABD, 28-31 Ekim 2012, pp.675-675
17. Goldin G., Zagar T., Fayda M, Marks L., Fried D., Miller S., Chen R., Schreiber Ec E., Egan T., Morris D., “Clinical Outcomes Of Cyberknife Radiosurgery For Early Stage Lung Cancer: Low Chest Wall Toxicity Rates Associated With Tracking”, JOURNAL OF THORACIC ONCOLOGY, PHILADELPHIA, ABD, 15-15 Eylül 2012, pp.274-275
18. Fayda M, Riguera D., Yirmibeşoğlu E., Laxrence M., Rivera P., Xie L., Stefanescu M., Marks L., “The Lack Of Association Between Cardiopulmonary Dosimetric Parameters And Short-Term Changes In Quality Of Life Following Thoracic Irradiation”, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, NEW YORK, ABD, 1-1 Ocak 2011, pp.604-605
19. Özkurt E, Tükenmez M, Çelet B, Öner G, Güven E, Müslümanoğlu M, İğci A, Özmen V, Fayda M, Cabioğlu N. Radiotherapy Does Not Increase Implant/Expander Loss in Breast Cancer Patients Who Underwent Immediate Breast Reconstruction. Annals of Surgical Oncology, Supplement Volume 22(2);May, 2015
20. Karanlık H, Fayda M, ilker Ö, Kurul S. COMPARISON OF IMPLANT-BASED IMMEDIATE BREAST RECONSTRUCTION WITH AND WITHOUT VICRYL MESH. 14. St. Gallen International Breast Cancer Conference, 2015.
21. Tükenmez M, Kulle CB, Velidedeoğlu M, Agcaoglu O, Parlakgul G, Aydogan F, Onder S, Bozdogan A, Ozkurt E, Muslumanoglu M, İgci A, Dinccag A, Özmen V, ÇELİK Varol, Karanlık H, Fayda M, Şen F, Aydıner A, Cabioğlu N. Clinical distuingishing characteristics and management of phyllodes tumors of the breast. 2015 ASCO Annual Meeting, 33(5), 12060
22. Çelet BÖ, Kozanoglu E, Soluk MT, Fayda M. Early fat grafting following PMRT improves cosmetic outcome in two-stage breast reconstruction. Barcelona Breast Meeting 11-13 Mart 2015
23. Fayda M. Is Sentinel Lymph Node Biopsy Enough for Axillary Macrometastasis? World Congress on Breast Cancer, Birmingham, UK, 2-4 August 2015
24. Fayda M Local-Regional Therapy Considerations in Patients Receiving Preoperative Chemotherapy. SUNY – YÖK Joint International Public Health and Medical Sciences Conference, April 2015.
25. Karanlık H, Bayrak S, Fayda M, Özgür İ, Kurul S. Comparison of implant-based immediate breast reconstruction with and without vicryl mesh. 14 th St. Gallen International Breast Cancer ConferencePrimary Therapy of Early Breast Cancer, 2015, 24(1), 132-132.
26. Karanlık H, Saip P, Fayda M, Yavuz E, Eralp Y, Küçücük S, Kurul S, Aydıner A. Magnetic resonance imaging as a predictor of pathologic response rates in patients treated with neoadjuvant chemotherapy. 9th European Breast Cancer Conference (EBCC), 2014, 50(2), 154.
27. Altun M, Tambaş M, Fayda M (2014). Nasopharyngeal carcinoma patients with new primaries. ASCO Annual Meeting 2014, 32(5), 6087.
28. Karabulut S, Tas F, Tastekin D, Karabulut M, Yasasever CT, Çiftçi R, Güveli M, Fayda M, Vatansever S, Serilmez M, Disci R, Aydıner A. The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer. Tumour Biology. 2014 Jun 3. [Epub ahead of print] PMID: 24891186.
29. Fayda M, Karanlik H. Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer. Lancet Oncol. 2013 Jun;14(7):e250. PMID: 23725703.
30. Fayda M, Kebudi R, Dizdar Y, Gorgun O, Gun F, Aksu G, Ayan I. Spontaneous pneumothorax in children with osteosarcoma: report of three cases and review of the literature. Acta Chir Belg. 2012 Sep-Oct;112(5):378-81. PMID: 23175928
31. Yirmibesoglu E, Higginson DS, Fayda M, Rivera MP, Halle J, Rosenman J, Xie L, Marks LB. Challenges scoring radiation pneumonitis in patients irradiated for lung cancer. Lung Cancer. 2012 Jun;76(3):350-3. PMID: 22230037
32. Fayda M, Chen R. Axillary vs sentinel lymph node dissection for invasive breast cancer. JAMA. 2011 Jun 8;305(22):2289; author reply 2290-1. PMID: 21642673
33. Fayda M, Aksu G, Agaoglu FY, Karadeniz A, Darendeliler E, Altun M, Hafiz G. The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: review of 30 cases. J Craniomaxillofac Surg. 2009 Jan;37(1):42-8. Epub 2008 Sep 18. PubMed PMID: 18804382.
34. Inan N, Fayda M, G. Aksu, G. Akansel, B. Muezzinoglu ve A. Arslan. “Leiomyoma of the Seminal Vesicle Mimicking Tumoral Extension of Prostatic Carcinoma.” Acta Chir Belg, 109, 811-814 (2009). PubMed PMID: 20184078.
35. Dizdar Y, Küçücük S, Sağlam SK, Fayda M, Uzel O, Camlıca H. Clinical Efficacy of Transdermal Fentanyl in Adults with Cancer-Related Pain:An Open Multicentre Study. Turkiye Klinikleri J Med Sci 2009;29(4):821-5.
36. Iş G, Taş S, Corapcioğlu F, Fayda M. Is it destiny or just migration pathway theory? Familial germ cell tumor with the same histopathologic subtype in a father and son. Pediatr Neurosurg. 2009;45(2):160. Epub 2009 Mar 25. PubMed PMID:19321956.
37. Aksu G, Fayda M, Saynak M, Karadeniz A. Spinal cord compression due to vertebral hemangioma. Orthopedics. 2008 Feb;31(2):169. PubMed PMID: 19292199.
38. Uygun K, Bilici A, Karagol H, Caloglu M, Cicin I, Aksu G, Fayda M, Uzunoglu S. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2009Aug;64(3):601-5. Epub 2009 Jan 3. PubMed PMID: 19123002.
39. Uygun K, Aksu G, Cicin I, Karagol H, Kocak Z, Fayda M, Binici A, Uzunoglu F. The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. Med Oncol. 2008;25(4):408-14. Epub 2008 Mar 5. PubMed PMID: 18320363.
40. Yalug I, Corapcioglu F, Fayda M, Aksu G, Basar E, Yalug K, Aker T. Posttraumatic stress disorder and risk factors in parents of children with a cancer diagnosis. Pediatr Hematol Oncol. 2008 Jan-Feb;25(1):27-38. PubMed PMID:18231952.
41. Kaytan E, Karadeniz A, Alici S, Fayda M, Kizir A. Unusual metastases from rectal adenocarcinoma; report of two cases with literature review. J BUON. 2002 Oct-Dec;7(4):377-80. PubMed PMID: 17955584.
42. Cakir A, Bilge H, Küçücük H, Okutan M, Fayda M, Darendeliler E. Effect of field placement errors on dose at junction between divergence matching and half-beam block techniques in craniospinal irradiation. J BUON. 2002 Oct-Dec;7(4):361-4. PubMed PMID: 17955581.
43. Karadeniz A, Saynak M, Kadehci Z, Fayda M, Aksu G, Kocaelli H, Hafiz G. [The results of combined treatment (surgery and postoperative radiotherapy) for tongue cancer and prognostic factors]. Kulak Burun Bogaz Ihtis Derg. 2007;17(1):1-6. Turkish. PubMed PMID: 17483603.
44. Aksu G, Karadeniz A, Fayda M, Dizdaroglu F. The effect of epithelial and myoepithelial differentiations on survival in a parotid gland undifferentiated carcinoma: case report and review of the literature. J BUON. 2003Oct-Dec;8(4):389-92. PubMed PMID: 17472283.
45. Cakir A, Bilge H, Dadaşbilge AK, Fayda M, Okutan M, Küçücük H. Do collimator angle setup errors cause dose inhomogeneity at the junction zone during craniospinal irradiation? A phantom study. J BUON. 2004 Apr-Jun;9(2):193-6. PubMed PMID: 17415814.
46. Aksu G, Ulutin C, Fayda M, Saynak M. Cerebellar and multiple spinal hemangioblastomas and intraventricular meningioma managed with subtotal resection and external beam radiotherapy; report of a case with literature review. J BUON. 2005 Jul-Sep;10(3):405-9. PubMed PMID: 17357198.
47. Saynak M, Aksu G, Fayda M, Kaytan E, Oral E, Gurocak S, Kizir A, Karadeniz A. The results of concomitant and sequential chemoradiotherapy with cisplatin and etoposide in patients with locally advanced non-small cell lung cancer. J BUON. 2005 Apr-Jun;10(2):213-8. PubMed PMID: 17343331.
48. Arslan M, Karadeniz AN, Aksu G, Güveli M, Fayda M, Doğan AK, Akyüz F. Postoperative hypofractionated radiotherapy in glioblastoma multiforme. J BUON. 2006 Jan-Mar;11(1):39-42. PubMed PMID: 17318950.
49. Ulutin C, Cetinayak O, Aksu G, Fayda M, Ataergin S, Beyzadeoğlu M. Malignant peripheral primitive neuroectodermal (pPNET) of tongue. Auris Nasus Larynx. 2007 Mar;34(1):115-8. Epub 2007 Jan 19. Review. PubMed PMID: 17240098.
50. Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M. Primary glioblastoma multiforme in younger patients: a single-institution experience. Tumori. 2006 Sep-Oct;92(5):407-11. PubMed PMID: 17168433.
51. Aksu G, Kucucuk S, Fayda M, Saynak M, Baskaya S, Saip P, Ozturk N, Aslay I. The role of postoperative radiotherapy in node negative breast cancer patients with pT3-T4 disease. Eur J Surg Oncol. 2007 Apr;33(3):285-93. Epub 2006 Dec 4. PubMed PMID: 17145158.
52. Ulutin HC, Aksu G, Fayda M, Kuzhan O, Tahmaz L, Beyzadeoglu M. The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience. Tumori. 2006 May-Jun;92(3):202-6. PubMed PMID: 16869236.
53. Bakkal BH, Kaya B, Berberoglu S, Aksu G, Sayin MY, Altundag MB, Fayda M. The efficiency of different chemoradiotherapy regimens in patients with paediatric nasopharynx cancer: review of 46 cases. Int J Clin Pract. 2007 Jan;61(1):52-61. Epub 2006 Jun 19. PubMed PMID: 16787436.
54. Aksu G, Fayda M, Saynak M, Tore G, Alatli C. Is early postradiation dysplasia almost associated with poor prognosis? A case report and review of the literature. Int J Gynecol Cancer. 2006 Mar-Apr;16(2):934-6. PubMed PMID: 16681791.
55. Aksu G, Karadeniz A, Saynak M, Fayda M, Kadehci Z, Kocaelli H. Treatment results and prognostic factors in oral tongue cancer: analysis of 80 patients. Int J Oral Maxillofac Surg. 2006 Jun;35(6):506-13. Epub 2006 Feb 28. PubMed PMID:16503396.
56. Ulutin HC, Fayda M. Retrospective, single-institution study on patterns of failure in male breast carcinoma patients after external beam radiotherapy. Tumori. 2005 Sep-Oct;91(5):443; author reply 443. PubMed PMID: 16459646.
57. Agaoglu FY, Fayda M, Dizdar Y, Basaran M, Yazar A, Darendeliler E. Primary uterine lymphoma: case report and literature review. Aust N Z J Obstet Gynaecol. 2005 Feb;45(1):88-9. PubMed PMID: 15730377.
58. Aksu G, Fayda M, Sakar B, Kapran Y. Colon cancer with isolated metastasis to the kidney at the time of initial diagnosis. Int J Gastrointest Cancer. 2003;34(2-3):73-7. PubMed PMID: 15361638.
2. Ozen A, Fayda M. Cardiotoxicity After the Lymphoma. Turk J Oncol 2022;37(Supp 1):44–50
3. Türkkan G, Fayda M. Abdominopelvik oligometastatik hastalıkta MRgRT. Özyar E, Önal HC, Fayda M, Selek U, editörler. Radyoterapide Yeni Bir Teknoloji: MR-Linak'ın Güncel Kullanımı. 1. Baskı. Ankara: Türkiye Klinikleri; 2022. p.57-61
4. Turkkan G, Bilici N, Sertel H, Keskus Y, Alkaya S, Tavli B, Ozkirim M, Fayda M. Clinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy. Front Oncol. 2022 Aug 16;12:909402. doi: 10.3389/fonc.2022.909402. PMID: 36052268; PMCID: PMC9424496.
5. Tambas M, Tavli B, Bilici N, Dizman A, Sertel H, Fayda M. Computed Tomography-Guided Optimization of Needle Insertion for Combined Intracavitary/Interstitial Brachytherapy With Utrecht Applicator in Locally Advanced Cervical Cancer. Pract Radiat Oncol. 2021 Jul-Aug;11(4):272-281. doi: 10.1016/j.prro.2021.01.008. Epub 2021 Feb 5. PMID: 33556579.
6. Turkkan, G, Bilici N, Sertel H, Tavlı B, Özkırım M, Fayda M. Dosimetric Comparison of Volumetric Modulated Arc Therapy and Dynamic Conformal Arc Therapy in Three fraction Single-isocenter Stereotactic Radiosurgery for Multiple Brain Metastases. Turk J Oncol 2022;37(1):67–73
7.Onder S, Fayda M, Karanlık H, Bayram A, Şen F, Cabioglu N, Tuzlalı S, İlhan R, ve Yavuz E. Loss of ARID1A expression is associated with poor prognosis in invasive micropapillary carcinomas of the breast: A clinicopathologic and immunohistochemical study with long-term survival analysis. Breast J. 2017 May 23. doi: 10.1111/tbj.12823. [Epub ahead of print]
8. Tambaş M, Fayda M. Yaşlıda Santral Sinir Sistemi Kanserleri. Saka B, editör. Geriatrik Onkoloji. Ankara: Türkiye Klinikleri; 2018. p. 28-35.
9. Fayda M, Gezer U. GAS5 oligonucleotides as therapeutic agents in breast cancer. Transl Cancer Res doi: 10.21037/tcr.2016.08.4 (2016).
10. Fayda M, Isin M, Tambas M, Guveli M, Meral R, Altun M, Sahin D, Ozkan G, Sanli Y, Isin H, Ozgur E, Gezer U. Do Circulating Long Non-Coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) Predict the Treatment Response in Patients with Head and Neck Cancer Treated with Chemoradiotherapy? Tumor Biology, 2015, 19 October, DOI: 10.1007/s13277-015-4189-1.
11. Fayda M, Tambaş, M, Karanlık H. Is sentinel lymph node biopsy enough for axillary macrometastasis? Turkish Journal of Surgery, 2015, Vol 31(4), pp. 253-255.
12. Aydiner A, Sen F, Tambas M, Ciftci R, Eralp Y, Saip P, Karanlik H, Fayda M, Kucucuk S, Onder S, Yavuz E, Muslumanoglu M, Igci A.Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment. Medicine (Baltimore), 2015 Dec;94(52):e2341.
13. Karanlık H, Özgür İ, Şahin D, Fayda M, Önder S, Yavuz E. Intraoperative ultrasound reduces the need for re-excision in breast conserving surgery, World Journal of Surgical Oncology, 2015 Nov 24;13(1):321.
14. Goldin G., Zagar T., Carter J., Fayda M, Prasad S., Fakiris S., Chen R., Morris D., Marks L., Schreiber E., Stereotactic Body Radiation Therapy For Early Stage Lung Cancer:Quantifying The Effect Of Tracking With Respiratory Motion On Chest Wall Dosimetry, American Society for Radiation Oncology 55th Annual Meeting, USA, 22-25 September 2013, vol.87, pp.733-734
15. Çakır A, Akgün Z, Fayda M, Ağaoğlu F. Comparison of three dimensional conformal radiation therapy, intensity modulated radiation therapy and volumetric modulated arc therapy for low radiation exposure of normal tissue in patients with prostate cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16(8), 3365-3370.
16. Fried D., Miller S., Fayda M, Morris D., Zagar T., Lawrence M., Schreiber E., Ivanoviç M., Mccartney W., Marks L., “Estimating The Alpha/Beta Ratio For Radiation-Induced Ct Density Changes In Patients Receiving Thoracic Radiation: Comparison Of Data From Srs And Conventional Fractionation”, 54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), BOSTON, ABD, 28-31 Ekim 2012, pp.675-675
17. Goldin G., Zagar T., Fayda M, Marks L., Fried D., Miller S., Chen R., Schreiber Ec E., Egan T., Morris D., “Clinical Outcomes Of Cyberknife Radiosurgery For Early Stage Lung Cancer: Low Chest Wall Toxicity Rates Associated With Tracking”, JOURNAL OF THORACIC ONCOLOGY, PHILADELPHIA, ABD, 15-15 Eylül 2012, pp.274-275
18. Fayda M, Riguera D., Yirmibeşoğlu E., Laxrence M., Rivera P., Xie L., Stefanescu M., Marks L., “The Lack Of Association Between Cardiopulmonary Dosimetric Parameters And Short-Term Changes In Quality Of Life Following Thoracic Irradiation”, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, NEW YORK, ABD, 1-1 Ocak 2011, pp.604-605
19. Özkurt E, Tükenmez M, Çelet B, Öner G, Güven E, Müslümanoğlu M, İğci A, Özmen V, Fayda M, Cabioğlu N. Radiotherapy Does Not Increase Implant/Expander Loss in Breast Cancer Patients Who Underwent Immediate Breast Reconstruction. Annals of Surgical Oncology, Supplement Volume 22(2);May, 2015
20. Karanlık H, Fayda M, ilker Ö, Kurul S. COMPARISON OF IMPLANT-BASED IMMEDIATE BREAST RECONSTRUCTION WITH AND WITHOUT VICRYL MESH. 14. St. Gallen International Breast Cancer Conference, 2015.
21. Tükenmez M, Kulle CB, Velidedeoğlu M, Agcaoglu O, Parlakgul G, Aydogan F, Onder S, Bozdogan A, Ozkurt E, Muslumanoglu M, İgci A, Dinccag A, Özmen V, ÇELİK Varol, Karanlık H, Fayda M, Şen F, Aydıner A, Cabioğlu N. Clinical distuingishing characteristics and management of phyllodes tumors of the breast. 2015 ASCO Annual Meeting, 33(5), 12060
22. Çelet BÖ, Kozanoglu E, Soluk MT, Fayda M. Early fat grafting following PMRT improves cosmetic outcome in two-stage breast reconstruction. Barcelona Breast Meeting 11-13 Mart 2015
23. Fayda M. Is Sentinel Lymph Node Biopsy Enough for Axillary Macrometastasis? World Congress on Breast Cancer, Birmingham, UK, 2-4 August 2015
24. Fayda M Local-Regional Therapy Considerations in Patients Receiving Preoperative Chemotherapy. SUNY – YÖK Joint International Public Health and Medical Sciences Conference, April 2015.
25. Karanlık H, Bayrak S, Fayda M, Özgür İ, Kurul S. Comparison of implant-based immediate breast reconstruction with and without vicryl mesh. 14 th St. Gallen International Breast Cancer ConferencePrimary Therapy of Early Breast Cancer, 2015, 24(1), 132-132.
26. Karanlık H, Saip P, Fayda M, Yavuz E, Eralp Y, Küçücük S, Kurul S, Aydıner A. Magnetic resonance imaging as a predictor of pathologic response rates in patients treated with neoadjuvant chemotherapy. 9th European Breast Cancer Conference (EBCC), 2014, 50(2), 154.
27. Altun M, Tambaş M, Fayda M (2014). Nasopharyngeal carcinoma patients with new primaries. ASCO Annual Meeting 2014, 32(5), 6087.
28. Karabulut S, Tas F, Tastekin D, Karabulut M, Yasasever CT, Çiftçi R, Güveli M, Fayda M, Vatansever S, Serilmez M, Disci R, Aydıner A. The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer. Tumour Biology. 2014 Jun 3. [Epub ahead of print] PMID: 24891186.
29. Fayda M, Karanlik H. Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer. Lancet Oncol. 2013 Jun;14(7):e250. PMID: 23725703.
30. Fayda M, Kebudi R, Dizdar Y, Gorgun O, Gun F, Aksu G, Ayan I. Spontaneous pneumothorax in children with osteosarcoma: report of three cases and review of the literature. Acta Chir Belg. 2012 Sep-Oct;112(5):378-81. PMID: 23175928
31. Yirmibesoglu E, Higginson DS, Fayda M, Rivera MP, Halle J, Rosenman J, Xie L, Marks LB. Challenges scoring radiation pneumonitis in patients irradiated for lung cancer. Lung Cancer. 2012 Jun;76(3):350-3. PMID: 22230037
32. Fayda M, Chen R. Axillary vs sentinel lymph node dissection for invasive breast cancer. JAMA. 2011 Jun 8;305(22):2289; author reply 2290-1. PMID: 21642673
33. Fayda M, Aksu G, Agaoglu FY, Karadeniz A, Darendeliler E, Altun M, Hafiz G. The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: review of 30 cases. J Craniomaxillofac Surg. 2009 Jan;37(1):42-8. Epub 2008 Sep 18. PubMed PMID: 18804382.
34. Inan N, Fayda M, G. Aksu, G. Akansel, B. Muezzinoglu ve A. Arslan. “Leiomyoma of the Seminal Vesicle Mimicking Tumoral Extension of Prostatic Carcinoma.” Acta Chir Belg, 109, 811-814 (2009). PubMed PMID: 20184078.
35. Dizdar Y, Küçücük S, Sağlam SK, Fayda M, Uzel O, Camlıca H. Clinical Efficacy of Transdermal Fentanyl in Adults with Cancer-Related Pain:An Open Multicentre Study. Turkiye Klinikleri J Med Sci 2009;29(4):821-5.
36. Iş G, Taş S, Corapcioğlu F, Fayda M. Is it destiny or just migration pathway theory? Familial germ cell tumor with the same histopathologic subtype in a father and son. Pediatr Neurosurg. 2009;45(2):160. Epub 2009 Mar 25. PubMed PMID:19321956.
37. Aksu G, Fayda M, Saynak M, Karadeniz A. Spinal cord compression due to vertebral hemangioma. Orthopedics. 2008 Feb;31(2):169. PubMed PMID: 19292199.
38. Uygun K, Bilici A, Karagol H, Caloglu M, Cicin I, Aksu G, Fayda M, Uzunoglu S. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2009Aug;64(3):601-5. Epub 2009 Jan 3. PubMed PMID: 19123002.
39. Uygun K, Aksu G, Cicin I, Karagol H, Kocak Z, Fayda M, Binici A, Uzunoglu F. The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. Med Oncol. 2008;25(4):408-14. Epub 2008 Mar 5. PubMed PMID: 18320363.
40. Yalug I, Corapcioglu F, Fayda M, Aksu G, Basar E, Yalug K, Aker T. Posttraumatic stress disorder and risk factors in parents of children with a cancer diagnosis. Pediatr Hematol Oncol. 2008 Jan-Feb;25(1):27-38. PubMed PMID:18231952.
41. Kaytan E, Karadeniz A, Alici S, Fayda M, Kizir A. Unusual metastases from rectal adenocarcinoma; report of two cases with literature review. J BUON. 2002 Oct-Dec;7(4):377-80. PubMed PMID: 17955584.
42. Cakir A, Bilge H, Küçücük H, Okutan M, Fayda M, Darendeliler E. Effect of field placement errors on dose at junction between divergence matching and half-beam block techniques in craniospinal irradiation. J BUON. 2002 Oct-Dec;7(4):361-4. PubMed PMID: 17955581.
43. Karadeniz A, Saynak M, Kadehci Z, Fayda M, Aksu G, Kocaelli H, Hafiz G. [The results of combined treatment (surgery and postoperative radiotherapy) for tongue cancer and prognostic factors]. Kulak Burun Bogaz Ihtis Derg. 2007;17(1):1-6. Turkish. PubMed PMID: 17483603.
44. Aksu G, Karadeniz A, Fayda M, Dizdaroglu F. The effect of epithelial and myoepithelial differentiations on survival in a parotid gland undifferentiated carcinoma: case report and review of the literature. J BUON. 2003Oct-Dec;8(4):389-92. PubMed PMID: 17472283.
45. Cakir A, Bilge H, Dadaşbilge AK, Fayda M, Okutan M, Küçücük H. Do collimator angle setup errors cause dose inhomogeneity at the junction zone during craniospinal irradiation? A phantom study. J BUON. 2004 Apr-Jun;9(2):193-6. PubMed PMID: 17415814.
46. Aksu G, Ulutin C, Fayda M, Saynak M. Cerebellar and multiple spinal hemangioblastomas and intraventricular meningioma managed with subtotal resection and external beam radiotherapy; report of a case with literature review. J BUON. 2005 Jul-Sep;10(3):405-9. PubMed PMID: 17357198.
47. Saynak M, Aksu G, Fayda M, Kaytan E, Oral E, Gurocak S, Kizir A, Karadeniz A. The results of concomitant and sequential chemoradiotherapy with cisplatin and etoposide in patients with locally advanced non-small cell lung cancer. J BUON. 2005 Apr-Jun;10(2):213-8. PubMed PMID: 17343331.
48. Arslan M, Karadeniz AN, Aksu G, Güveli M, Fayda M, Doğan AK, Akyüz F. Postoperative hypofractionated radiotherapy in glioblastoma multiforme. J BUON. 2006 Jan-Mar;11(1):39-42. PubMed PMID: 17318950.
49. Ulutin C, Cetinayak O, Aksu G, Fayda M, Ataergin S, Beyzadeoğlu M. Malignant peripheral primitive neuroectodermal (pPNET) of tongue. Auris Nasus Larynx. 2007 Mar;34(1):115-8. Epub 2007 Jan 19. Review. PubMed PMID: 17240098.
50. Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M. Primary glioblastoma multiforme in younger patients: a single-institution experience. Tumori. 2006 Sep-Oct;92(5):407-11. PubMed PMID: 17168433.
51. Aksu G, Kucucuk S, Fayda M, Saynak M, Baskaya S, Saip P, Ozturk N, Aslay I. The role of postoperative radiotherapy in node negative breast cancer patients with pT3-T4 disease. Eur J Surg Oncol. 2007 Apr;33(3):285-93. Epub 2006 Dec 4. PubMed PMID: 17145158.
52. Ulutin HC, Aksu G, Fayda M, Kuzhan O, Tahmaz L, Beyzadeoglu M. The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience. Tumori. 2006 May-Jun;92(3):202-6. PubMed PMID: 16869236.
53. Bakkal BH, Kaya B, Berberoglu S, Aksu G, Sayin MY, Altundag MB, Fayda M. The efficiency of different chemoradiotherapy regimens in patients with paediatric nasopharynx cancer: review of 46 cases. Int J Clin Pract. 2007 Jan;61(1):52-61. Epub 2006 Jun 19. PubMed PMID: 16787436.
54. Aksu G, Fayda M, Saynak M, Tore G, Alatli C. Is early postradiation dysplasia almost associated with poor prognosis? A case report and review of the literature. Int J Gynecol Cancer. 2006 Mar-Apr;16(2):934-6. PubMed PMID: 16681791.
55. Aksu G, Karadeniz A, Saynak M, Fayda M, Kadehci Z, Kocaelli H. Treatment results and prognostic factors in oral tongue cancer: analysis of 80 patients. Int J Oral Maxillofac Surg. 2006 Jun;35(6):506-13. Epub 2006 Feb 28. PubMed PMID:16503396.
56. Ulutin HC, Fayda M. Retrospective, single-institution study on patterns of failure in male breast carcinoma patients after external beam radiotherapy. Tumori. 2005 Sep-Oct;91(5):443; author reply 443. PubMed PMID: 16459646.
57. Agaoglu FY, Fayda M, Dizdar Y, Basaran M, Yazar A, Darendeliler E. Primary uterine lymphoma: case report and literature review. Aust N Z J Obstet Gynaecol. 2005 Feb;45(1):88-9. PubMed PMID: 15730377.
58. Aksu G, Fayda M, Sakar B, Kapran Y. Colon cancer with isolated metastasis to the kidney at the time of initial diagnosis. Int J Gastrointest Cancer. 2003;34(2-3):73-7. PubMed PMID: 15361638.
Titles of my last speechs
•"Radiotherapy in oligometastatic breast cancer", 9th Uludağ Breast Cancer Symposium, Bursa Merinos AKKM, June 2024
•"Basic Hybrid Brachytherapy applications in gynecological cancers", Fayda Science Foundation Seminars-1, Liv Hospital-Ulus. May 2024
•"Radiotherapy in Skin Cancers", Medeniyet University Plastic Surgery and Dermatology Department Training Program, May 2024
•"Radiation Therapy in Stomach Cancer. To Whom, How, When", Current Treatment Approaches in Stomach Cancer-2024. Diagnosis, Surgery and Oncological Treatment. Liv Hospital Ulus, April 2024
•"High Precision Radiotherapy with 1.5 Tesla Mr-Linac", 6th Saudi Association of Radiation Oncology Meeting. Jeddah, April 2024
•"Radiotherapy in brain metastases", Florence Nightingale Hospital, February 2024
•"Conventional radiotherapy or SBRT in locally advanced Pancreatic Cancer? " 15th National Radiation Oncology Congress, Antalya, December 2023
•"Advanced treatment using VersaHD with SRT/SABR focus" Foundation Lala Salma days in Tangiers, Morocco, November 2023
•"Use of HDR prostate brachytherapy in high-risk patients" Urooncology congress, Antalya, November 2023
•"Radiotherapy technician symposium" Liv Hospital Ulus, Istanbul, October 2023
•"Does the genomics of breast cancer affect radiotherapy indications and fields?" Liv Hospital Vadi Istanbul, October 2023
•"Radiotherapy approach in peritoneal tumors" Istanbul, June 2023
•"High precision radiotherapy with 1.5 Tesla MR-linac" Uzbekistan, May 2023
•"Modern radiotherapy approaches with Versa HD-RS" Pakistan, February 2023
•"High precision radiotherapy with 1.5 Tesla MR-linac" Pakistan, February 2023
•"Where are we in hypofractionated breast radiotherapy?" Current Developments in Breast Cancer Meeting, December 2022
•"Gynecological and prostate interstitial brachytherapy" Kuwait, November 2022
•"Radiotherapy for undiagnosed nodule. To whom, when, how?" Management of pulmonary nodules Meeting, Liv Hospital Istanbul, May 2022
• “UNITY 1.5 Tesla MR-linac in Busy Clinic" European Society for RAditherapy and Oncology (ESTRO) May 2022, Copenhagen, Denmark
• “1.5 Tesla Mr Guided radiotherapy in rectal and abdominal tumors” Elekta Mastercourse webinar March 2022
• “Elekta Philips Lunch Symposium The future of MR RT and clinical experience” Dubai, Arab Health 2022
• “Elekta VIP Gala MR Guided RT and Clinical Cases, importance and necessity of hypofractionation” Dubai, Arab Health 2022
• “Thoracic oncology radiation oncology perspective” Thoracic Oncology Review meeting organized by Smart Health Tower-Scientific Affair, Iraq, February 2022
• “Choosing the right aplicator for gynaecological brachytherapy” International webinar. December 2021
• “UNITY 1.5 Tesla MR-Linac radiotherapy, Future of radiation oncology” International Liv Hospital Expo Meeting, Istanbul, December 2021
• “Target oriented Radiotherapy” International Liv Hospital Expo Meeting, Istanbul, December 2021
• “Low risk recurrence tumor in elderly women” Discussant. Breast Health Working Group (BHWG) International Meeting, İstanbul, October 2021
• "Can we omit RT in pts with low - risk loco- regional recurrence?" Chair. Breast Healty Working Group International Meeting, İstanbul, October 2021
• Lymphatic radiotherapy in breast cancer " Uptodate Management of axilla in breast cancer meeting. İstanbul, October 2021.
• "Brachytherapy clinical experience" ARCON, Nigeria Radiation Oncology Meeting. Nigeria September 2021
•"Basic Hybrid Brachytherapy applications in gynecological cancers", Fayda Science Foundation Seminars-1, Liv Hospital-Ulus. May 2024
•"Radiotherapy in Skin Cancers", Medeniyet University Plastic Surgery and Dermatology Department Training Program, May 2024
•"Radiation Therapy in Stomach Cancer. To Whom, How, When", Current Treatment Approaches in Stomach Cancer-2024. Diagnosis, Surgery and Oncological Treatment. Liv Hospital Ulus, April 2024
•"High Precision Radiotherapy with 1.5 Tesla Mr-Linac", 6th Saudi Association of Radiation Oncology Meeting. Jeddah, April 2024
•"Radiotherapy in brain metastases", Florence Nightingale Hospital, February 2024
•"Conventional radiotherapy or SBRT in locally advanced Pancreatic Cancer? " 15th National Radiation Oncology Congress, Antalya, December 2023
•"Advanced treatment using VersaHD with SRT/SABR focus" Foundation Lala Salma days in Tangiers, Morocco, November 2023
•"Use of HDR prostate brachytherapy in high-risk patients" Urooncology congress, Antalya, November 2023
•"Radiotherapy technician symposium" Liv Hospital Ulus, Istanbul, October 2023
•"Does the genomics of breast cancer affect radiotherapy indications and fields?" Liv Hospital Vadi Istanbul, October 2023
•"Radiotherapy approach in peritoneal tumors" Istanbul, June 2023
•"High precision radiotherapy with 1.5 Tesla MR-linac" Uzbekistan, May 2023
•"Modern radiotherapy approaches with Versa HD-RS" Pakistan, February 2023
•"High precision radiotherapy with 1.5 Tesla MR-linac" Pakistan, February 2023
•"Where are we in hypofractionated breast radiotherapy?" Current Developments in Breast Cancer Meeting, December 2022
•"Gynecological and prostate interstitial brachytherapy" Kuwait, November 2022
•"Radiotherapy for undiagnosed nodule. To whom, when, how?" Management of pulmonary nodules Meeting, Liv Hospital Istanbul, May 2022
• “UNITY 1.5 Tesla MR-linac in Busy Clinic" European Society for RAditherapy and Oncology (ESTRO) May 2022, Copenhagen, Denmark
• “1.5 Tesla Mr Guided radiotherapy in rectal and abdominal tumors” Elekta Mastercourse webinar March 2022
• “Elekta Philips Lunch Symposium The future of MR RT and clinical experience” Dubai, Arab Health 2022
• “Elekta VIP Gala MR Guided RT and Clinical Cases, importance and necessity of hypofractionation” Dubai, Arab Health 2022
• “Thoracic oncology radiation oncology perspective” Thoracic Oncology Review meeting organized by Smart Health Tower-Scientific Affair, Iraq, February 2022
• “Choosing the right aplicator for gynaecological brachytherapy” International webinar. December 2021
• “UNITY 1.5 Tesla MR-Linac radiotherapy, Future of radiation oncology” International Liv Hospital Expo Meeting, Istanbul, December 2021
• “Target oriented Radiotherapy” International Liv Hospital Expo Meeting, Istanbul, December 2021
• “Low risk recurrence tumor in elderly women” Discussant. Breast Health Working Group (BHWG) International Meeting, İstanbul, October 2021
• "Can we omit RT in pts with low - risk loco- regional recurrence?" Chair. Breast Healty Working Group International Meeting, İstanbul, October 2021
• Lymphatic radiotherapy in breast cancer " Uptodate Management of axilla in breast cancer meeting. İstanbul, October 2021.
• "Brachytherapy clinical experience" ARCON, Nigeria Radiation Oncology Meeting. Nigeria September 2021